Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052

Core Insights - Aclaris Therapeutics has initiated a Phase 1b proof-of-concept trial for ATI-052, a bispecific anti-TSLP/IL-4Rα antibody targeting atopic dermatitis [1][2] - The company is experiencing strong momentum in the clinical development of ATI-052, following positive Phase 1a interim results [2] - Aclaris plans to initiate a second Phase 1b trial for asthma in the first quarter of 2026, with top-line results from both trials expected in the second half of 2026 [3] Company Overview - Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases [5] - The company has a robust R&D engine and a multi-stage portfolio aimed at addressing unmet medical needs in patients with immuno-inflammatory conditions [5] Product Details - ATI-052 is designed to inhibit both thymic stromal lymphopoietin (TSLP) and interleukin-4 receptor (IL-4Rα), potentially offering a best-in-class treatment option for various atopic and immunologic diseases [4] - The antibody exhibits high affinity and potency, with engineered properties to extend its half-life, enhancing its therapeutic potential [4]